The Asia-Pacific immunoglobulin market is set to rise with a CAGR of 7.20% during the estimated years of 2022 to 2030, capturing a revenue share of $5479.96 million by 2030.
ASIA-PACIFIC IMMUNOGLOBULIN MARKET FORECAST 2022-2030
Asia-Pacific Immunoglobulin Market by Product (IGG, IGA, IGM, IGE, IGD) Market by Mode of Delivery (Intravenous Immunoglobulin, Subcutaneous Immunoglobulin, Intramuscular Immunoglobulin) Market by Application (Hypogamma Globulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura (ITB), Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre Syndrome, Other Applications) Market by Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, Other Distribution Channels) Market by End-user (Hospitals & Clinics, Homecare) by Geography
The Asia-Pacific immunoglobulin market is set to rise with a CAGR of 7.20% during the estimated years of 2022 to 2030, capturing a revenue share of $5479.96 million by 2030.
The launch of advanced and innovative immunoglobulin products, the increasing incidence of various disease types, and the rise in the geriatric population are among the key drivers facilitating the region’s market growth. However, the Asia-Pacific immunoglobulin market is likely to be restrained due to the high costs associated with product development.
To know more about this report, request a free sample copy
The Asia-Pacific immunoglobulin market growth analysis encompasses the evaluation of China, Japan, India, Australia, South Korea, Indonesia, Vietnam, Thailand, and Rest of Asia-Pacific. The expansion of plasma donation as well as collection stations, in addition to the rapidly growing geriatric populace, strategic initiatives undertaken by key players, and research and development activities primarily fuel the immunoglobulin market growth in China.
Moreover, as per the Plan of Yunnan Province for Setting up Plasma Collection Stations (2020-2023), issued in December 2020, the Health Commission of Yunnan Province has proposed to set up 24 plasma collection centers. This initiative would add 20 new plasma collection centers based on 4 pilot facilities across the province. Presently, Shanghai Blood Products has 2 pilot stations operational in Yunnan, with a total collection of nearly 42 tons.
On the other hand, Japan has observed a significant rise in immunoglobulin usage as well as consumption. The increase is primarily credited to the launch of concentrated preparations and indications for preventing chronic inflammatory demyelinating polyneuropathy progression. In this regard, the use of immunoglobulin for chronic inflammatory demyelinating polyneuropathy in Japan has demonstrated an upward trend. Market players are also developing advanced products for the treatment of various diseases, in addition to offering therapeutic benefits to patients. Therefore, these factors are expected to strengthen the immunoglobulin market growth in the Asia-Pacific across the forecast period.
The Asia-Pacific immunoglobulin market is mainly segmented into product, mode of delivery, application, distribution channel, and end-user. The application segment is further categorized into hypogamma globulinemia, primary immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, chronic inflammatory, demyelinating polyneuropathy, idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, inflammatory myopathies, specific antibody deficiency, and other applications. Hypogamma globulinemia is a problem linked to the immune system, thus preventing it from producing enough antibodies or immunoglobulins. Antibodies help the body recognize and fight off foreign invaders like viruses, fungi, and bacteria.
Chronic inflammatory demyelinating polyneuropathy is a neurological disease characterized by progressive weakness as well as deteriorated sensory function in the limbs. The disorder is also known as chronic relapsing polyneuropathy.
Some of the major players operating in the Asia-Pacific immunoglobulin market are Takeda Pharmaceutical Company Limited, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd, Shanghai RAAS Blood Products Co Ltd, etc.
Takeda Pharmaceutical Company Limited, headquartered in Japan, is a multinational pharmaceutical company. It is also one of the top 20 major pharmaceutical companies globally in terms of revenue.
Takeda Pharmaceutical Company Limited focuses on neurology, metabolic disorders, gastroenterology, inflammation, and oncology, through its independent subsidiary called Takeda Oncology.
Report Synopsis
| Report Scope | Details |
| Market Forecast Years | 2022-2030 |
| Base Year | 2021 |
| Market Historical Years | 2018-2021 |
| Forecast Units | Revenue ($ Million) |
| Segments Analyzed | Product, Mode of Delivery, Application, Distribution Channel, End-User |
| Countries Analyzed | China, Japan, India, Australia, South Korea, Indonesia, Vietnam, Thailand, and Rest of Asia-Pacific |
| Companies Analyzed | Biotest AG, China Biologic Products Inc, Grifols SA, LFB Group, CSL Behring, Kedrion, Octapharma AG, Takeda Pharmaceutical Company Limited, Bio Products Laboratory, Shanghai RAAS Blood Products Co Ltd, Pfizer Inc, Sanquin Plasma Products BV, ADMA Biologics, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd, Kamada Ltd |
To request a free sample copy of this report, please complete the form below:
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
- EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
- MARKET DYNAMICS
- KEY DRIVERS
- GROWTH IN GERIATRIC POPULATION
- PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS
- INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
- KEY RESTRAINTS
- HIGH COST OF THERAPY
- HIGH RISK OF SIDE EFFECTS
- KEY DRIVERS
- KEY ANALYTICS
- IMPACT OF COVID-19 ON IMMUNOGLOBULIN MARKET
- KEY MARKET TRENDS
- PORTER’S FIVE FORCES ANALYSIS
- BUYERS POWER
- SUPPLIERS POWER
- SUBSTITUTION
- NEW ENTRANTS
- INDUSTRY RIVALRY
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
- KEY BUYING CRITERIA
- SOURCE
- APPLICATION
- EPITOPE
- VALIDATION
- REGULATORY FRAMEWORK
- MARKET BY PRODUCT
- IGG
- IGA
- IGM
- IGE
- IGD
- MARKET BY MODE OF DELIVERY
- INTRAVENOUS IMMUNOGLOBULIN
- SUBCUTANEOUS IMMUNOGLOBULIN
- INTRAMUSCULAR IMMUNOGLOBULIN
- MARKET BY APPLICATION
- HYPOGAMMA GLOBULINEMIA
- CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
- PRIMARY IMMUNODEFICIENCY DISEASES
- MYASTHENIA GRAVIS
- MULTIFOCAL MOTOR NEUROPATHY
- IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
- INFLAMMATORY MYOPATHIES
- SPECIFIC ANTIBODY DEFICIENCY
- GUILLAIN-BARRE SYNDROME
- OTHER APPLICATIONS
- MARKET BY DISTRIBUTION CHANNEL
- HOSPITAL PHARMACY
- SPECIALTY PHARMACY
- OTHER DISTRIBUTION CHANNELS
- MARKET BY END-USER
- HOSPITALS & CLINICS
- HOMECARE
- GEOGRAPHICAL ANALYSIS
- ASIA-PACIFIC
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- COUNTRY ANALYSIS
- CHINA
- JAPAN
- INDIA
- SOUTH KOREA
- INDONESIA
- THAILAND
- VIETNAM
- AUSTRALIA
- REST OF ASIA-PACIFIC
- ASIA-PACIFIC
- COMPETITIVE LANDSCAPE
- KEY STRATEGIC DEVELOPMENTS
- MERGERS & ACQUISITIONS
- PRODUCT LAUNCHES & DEVELOPMENTS
- PARTNERSHIPS & AGREEMENTS
- BUSINESS EXPANSIONS & DIVESTITURES
- COMPANY PROFILES
- ADMA BIOLOGICS
- BIO PRODUCTS LABORATORY
- BIOTEST AG
- CHINA BIOLOGIC PRODUCTS INC
- CSL BEHRING
- GRIFOLS SA
- KAMADA LTD
- KEDRION BIOPHARMA
- LFB GROUP
- OCTAPHARMA AG
- PFIZER INC
- SANQUIN PLASMA PRODUCTS BV
- SHANGHAI RAAS BLOOD PRODUCTS CO LTD
- SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD
- TAKEDA PHARMACEUTICAL COMPANY LIMITED
- KEY STRATEGIC DEVELOPMENTS
LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – IMMUNOGLOBULIN
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY PRODUCT, HISTORICAL YEARS 2018-2021 (IN $ MILLION)
TABLE 4: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY PRODUCT, FORECAST YEARS 2022-2030 (IN $ MILLION)
TABLE 5: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, HISTORICAL YEARS 2018-2021 (IN $ MILLION)
TABLE 6: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, FORECAST YEARS 2022-2030 (IN $ MILLION)
TABLE 7: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, HISTORICAL YEARS 2018-2021 (IN $ MILLION)
TABLE 8: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, FORECAST YEARS 2022-2030 (IN $ MILLION)
TABLE 9: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS 2018-2021 (IN $ MILLION)
TABLE 10: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS 2022-2030 (IN $ MILLION)
TABLE 11: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY END-USER, HISTORICAL YEARS 2018-2021 (IN $ MILLION)
TABLE 12: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY END-USER, FORECAST YEARS 2022-2030 (IN $ MILLION)
TABLE 13: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY, HISTORICAL YEARS 2018-2021 (IN $ MILLION)
TABLE 14: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY, FORECAST YEARS 2022-2030 (IN $ MILLION)
TABLE 15: LEADING PLAYERS OPERATING IN ASIA-PACIFIC IMMUNOGLOBULIN MARKET
TABLE 16: LIST OF MERGERS & ACQUISITIONS
TABLE 17: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 18: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 19: LIST OF BUSINESS EXPANSIONS & DIVESTITURE
LIST OF FIGURES
FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER’S FIVE FORCES ANALYSIS
FIGURE 3: OPPORTUNITY MATRIX
FIGURE 4: VENDOR LANDSCAPE
FIGURE 5: KEY BUYING CRITERIA
FIGURE 6: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2021
FIGURE 7: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IGG, 2022-2030 (IN $ MILLION)
FIGURE 8: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IGA, 2022-2030 (IN $ MILLION)
FIGURE 9: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IGM, 2022-2030 (IN $ MILLION)
FIGURE 10: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IGE, 2022-2030 (IN $ MILLION)
FIGURE 11: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IGD, 2022-2030 (IN $ MILLION)
FIGURE 12: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY MODE OF DELIVERY, IN 2021
FIGURE 13: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY INTRAVENOUS IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)
FIGURE 14: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)
FIGURE 15: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)
FIGURE 16: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2021
FIGURE 17: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2030 (IN $ MILLION)
FIGURE 18: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2030 (IN $ MILLION)
FIGURE 19: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2030 (IN $ MILLION)
FIGURE 20: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2030 (IN $ MILLION)
FIGURE 21: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2030 (IN $ MILLION)
FIGURE 22: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2030 (IN $ MILLION)
FIGURE 23: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2030 (IN $ MILLION)
FIGURE 24: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2030 (IN $ MILLION)
FIGURE 25: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2030 (IN $ MILLION)
FIGURE 26: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2030 (IN $ MILLION)
FIGURE 27: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2021
FIGURE 28: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2030 (IN $ MILLION)
FIGURE 29: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2030 (IN $ MILLION)
FIGURE 30: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY OTHER DISTRIBUTION CHANNELS, 2022-2030 (IN $ MILLION)
FIGURE 31: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021
FIGURE 32: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2030 (IN $ MILLION)
FIGURE 33: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2030 (IN $ MILLION)
FIGURE 34: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
FIGURE 35: CHINA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 36: JAPAN IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 37: INDIA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 38: SOUTH KOREA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 39: INDONESIA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 40: THAILAND IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 41: VIETNAM IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 42: AUSTRALIA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 43: REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
- GEOGRAPHICAL ANALYSIS
- ASIA-PACIFIC
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- COUNTRY ANALYSIS
- CHINA
- JAPAN
- INDIA
- SOUTH KOREA
- INDONESIA
- THAILAND
- VIETNAM
- AUSTRALIA
- REST OF ASIA-PACIFIC
- ASIA-PACIFIC
- MARKET BY PRODUCT
- IGG
- IGA
- IGM
- IGE
- IGD
- MARKET BY MODE OF DELIVERY
- INTRAVENOUS IMMUNOGLOBULIN
- SUBCUTANEOUS IMMUNOGLOBULIN
- INTRAMUSCULAR IMMUNOGLOBULIN
- MARKET BY APPLICATION
- HYPOGAMMA GLOBULINEMIA
- CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
- PRIMARY IMMUNODEFICIENCY DISEASES
- MYASTHENIA GRAVIS
- MULTIFOCAL MOTOR NEUROPATHY
- IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
- INFLAMMATORY MYOPATHIES
- SPECIFIC ANTIBODY DEFICIENCY
- GUILLAIN-BARRE SYNDROME
- OTHER APPLICATIONS
- MARKET BY DISTRIBUTION CHANNEL
- HOSPITAL PHARMACY
- SPECIALTY PHARMACY
- OTHER DISTRIBUTION CHANNELS
- MARKET BY END-USER
- HOSPITALS & CLINICS
- HOMECARE
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.